June 4 (Reuters) - ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study ...
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the ...
Clinical Trials Arena on MSN
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit
The CLDN18.2-targeting asset is currently under priority review by China’s NMPA, which could see it join the country’s ...
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that ...
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...
ADC Therapeutics (ADCT) stock plunged as confirmatory late-stage trial data for the company's lymphoma therapy Zynlonta ...
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised ...
MedPage Today on MSN
Investigational ADC Ups Survival in Advanced Triple-Negative Breast Cancer
Izalontamab brengitecan more than doubled PFS compared with chemotherapy ...
Antibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating number of U.S. Food and Drug Administration (FDA) approvals and rapidly growing market size, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results